Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Terry A Jacobson

Showing results (161-170 of 182) with videos related to

Pageof 19
Sort By:
Journal of the American Heart Association|February 21, 2023
Cardiovascular Benefits of Icosapent Ethyl in Patients With and Without Atrial Fibrillation in REDUCE-ITBrian Olshansky, Deepak L Bhatt, Michael Miller, et al.
European Heart Journal. Cardiovascular Pharmacotherapy|October 3, 2020
REDUCE-IT INTERIM: accumulation of data across prespecified interim analyses to final resultsBrian Olshansky, Deepak L Bhatt, Michael Miller, et al.
Circulation|August 20, 2019
Omega-3 Fatty Acids for the Management of Hypertriglyceridemia: A Science Advisory From the American Heart AssociationAnn C Skulas-Ray, Peter W F Wilson, William S Harris, et al.
Journal of Clinical Lipidology|April 2, 2024
A focused update to the 2019 NLA scientific statement on use of lipoprotein(a) in clinical practiceMarlys L Koschinsky, Archna Bajaj, Michael B Boffa, et al.
Circulation|November 12, 2019
REDUCE-IT USA: Results From the 3146 Patients Randomized in the United StatesDeepak L Bhatt, Michael Miller, Eliot A Brinton, et al.
Journal of the American College of Cardiology|October 8, 2021
Comparative Reductions in Investigator-Reported and Adjudicated Ischemic Events in REDUCE-ITPrakriti Gaba, Deepak L Bhatt, Robert P Giugliano, et al.
Circulation|October 28, 2021
Benefits of Icosapent Ethyl Across the Range of Kidney Function in Patients With Established Cardiovascular Disease or Diabetes: REDUCE-IT RENALArjun Majithia, Deepak L Bhatt, Allon N Friedman, et al.
Journal of Clinical Lipidology|December 10, 2013
Use of health information technology (HIT) to improve statin adherence and low-density lipoprotein cholesterol goal attainment in high-risk patients: proceedings from a workshopJerome D Cohen, Karen E Aspry, Alan S Brown, et al.
JACC. Advances|August 21, 2025
Primary Prevention Aspirin, Lipoprotein(a), and Cardiorenal Outcomes in Chronic Kidney Disease: Chronic Renal Insufficiency CohortAlexander C Razavi, Jing Chen, Wei Yang, et al.
Journal of the American College of Cardiology|April 28, 2022
Prevention of Cardiovascular Events and Mortality With Icosapent Ethyl in Patients With Prior Myocardial InfarctionPrakriti Gaba, Deepak L Bhatt, Ph Gabriel Steg, et al.
Pageof 19

Showing results (161-170 of 182) with videos related to

Sort By:
Pageof 19
Journal of the American Heart Association|February 21, 2023
Cardiovascular Benefits of Icosapent Ethyl in Patients With and Without Atrial Fibrillation in REDUCE-ITBrian Olshansky, Deepak L Bhatt, Michael Miller, et al.
European Heart Journal. Cardiovascular Pharmacotherapy|October 3, 2020
REDUCE-IT INTERIM: accumulation of data across prespecified interim analyses to final resultsBrian Olshansky, Deepak L Bhatt, Michael Miller, et al.
Circulation|August 20, 2019
Omega-3 Fatty Acids for the Management of Hypertriglyceridemia: A Science Advisory From the American Heart AssociationAnn C Skulas-Ray, Peter W F Wilson, William S Harris, et al.
Journal of Clinical Lipidology|April 2, 2024
A focused update to the 2019 NLA scientific statement on use of lipoprotein(a) in clinical practiceMarlys L Koschinsky, Archna Bajaj, Michael B Boffa, et al.
Circulation|November 12, 2019
REDUCE-IT USA: Results From the 3146 Patients Randomized in the United StatesDeepak L Bhatt, Michael Miller, Eliot A Brinton, et al.
Journal of the American College of Cardiology|October 8, 2021
Comparative Reductions in Investigator-Reported and Adjudicated Ischemic Events in REDUCE-ITPrakriti Gaba, Deepak L Bhatt, Robert P Giugliano, et al.
Circulation|October 28, 2021
Benefits of Icosapent Ethyl Across the Range of Kidney Function in Patients With Established Cardiovascular Disease or Diabetes: REDUCE-IT RENALArjun Majithia, Deepak L Bhatt, Allon N Friedman, et al.
Journal of Clinical Lipidology|December 10, 2013
Use of health information technology (HIT) to improve statin adherence and low-density lipoprotein cholesterol goal attainment in high-risk patients: proceedings from a workshopJerome D Cohen, Karen E Aspry, Alan S Brown, et al.
JACC. Advances|August 21, 2025
Primary Prevention Aspirin, Lipoprotein(a), and Cardiorenal Outcomes in Chronic Kidney Disease: Chronic Renal Insufficiency CohortAlexander C Razavi, Jing Chen, Wei Yang, et al.
Journal of the American College of Cardiology|April 28, 2022
Prevention of Cardiovascular Events and Mortality With Icosapent Ethyl in Patients With Prior Myocardial InfarctionPrakriti Gaba, Deepak L Bhatt, Ph Gabriel Steg, et al.
Pageof 19